![]() |
市場調查報告書
商品編碼
1792399
多形性膠質母細胞瘤治療市場報告(按藥物類型、給藥途徑、分子類型、配銷通路和地區)2025-2033Glioblastoma Multiforme Treatment Market Report by Drug Type, Route of Administration, Type of Molecule, Distribution Channel, and Region 2025-2033 |
2024 年全球多形性膠質母細胞瘤治療市場規模達 23 億美元。展望未來, IMARC Group預計到 2033 年市場規模將達到 41 億美元,2025-2033 年期間的成長率 (CAGR) 為 6.39%。
多形性膠質母細胞瘤,又稱為IV級星狀細胞瘤,是一種惡性IV級腦瘤,會在腦細胞內快速擴散,並感染鄰近細胞。由於其細胞快速退化的特點,它會對腦部造成巨大壓力,導致嚴重的頭痛和癲癇。雖然該疾病的確切病因尚不清楚,但包括Turcot症候群等罕見遺傳性疾病在內的多種因素被認為是其病因。它是最致命的腦癌之一,並且具有治療抗藥性,患者確診後存活期極短。目前,該疾病的治療方法包括手術切除、化學治療和放射治療。
全球腫瘤疾病盛行率的上升和老齡人口的成長是推動市場成長的關鍵因素。此外,針對膠質瘤幹細胞抗藥性的先進治療方法的開發也對市場成長產生了積極影響。此外,分子生物技術和癌症及相關疾病基因治療領域的研發活動日益增多,促進了各種生物藥物的開發。這些藥物有助於減少現有治療方法的副作用,從而獲得更廣泛的患者接受。此外,全球多個政府為改善醫療基礎設施所採取的舉措,以及人們對各種療法可用性的認知不斷提高,預計將進一步為市場創造積極的前景。
The global glioblastoma multiforme treatment market size reached USD 2.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 4.1 Billion by 2033, exhibiting a growth rate (CAGR) of 6.39% during 2025-2033.
Glioblastoma multiforme, also known as grade IV astrocytoma, is a malignant grade IV brain tumor that rapidly spreads within the brain cells and can also infect the nearby cells. Since it is characterized by rapid cell degeneration, it creates immense pressure on the brain resulting in severe headaches and seizures. Although the exact cause of the diseases is still unknown, several factors including rare hereditary disorders such as Turcot syndrome are believed to be its cause. It is one of the most lethal forms of brain cancer and is treatment-resistant in nature, wherein the patient has an extremely short survival period post-diagnosis. The current treatment procedure of the disease includes surgical resection, chemotherapy and radiation.
Increasing prevalence of oncological diseases and a growing geriatric population across the globe are among the key factors driving the market growth. Furthermore, the development of advanced treatment methods that counter the resistive properties of glioma stem cells is also positively influencing the market growth. Additionally, increasing research and development (R&D) activities in molecular biotechnology and gene therapy for cancer and related diseases have facilitated the development of various biological drugs. These drugs assist in diminishing the side-effects of the existing treatment methods, thus creating broader acceptance amongst patients. Moreover, initiatives undertaken by several governments across the globe to improve healthcare infrastructure, along with the rising awareness of the availability of various therapies, are further expected to create a positive outlook for the market.
The report has also analysed the competitive landscape of the market with some of the key players being Sun Pharmaceutical Industries, Celldex Therapeutics, Pfizer, F. Hoffmann La Roche, Bristol-Myers Squibb, Teva Pharmaceuticals, Exelixis, Angiochem and Arbor Pharmaceuticals.
IMARC Group's latest report provides a deep insight into the global glioblastoma multiforme treatment market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the glioblastoma multiforme treatment market in any manner.